Key facts
- This page summarizes David Hallal's Form 4 filing for Allovir, Inc. (KLRS).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 07 Jun 2024, 16:05.
David Hallal - 06 Jun 2024 Form 4 Insider Report for Allovir, Inc. (KLRS)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- KLRS
- Reported as of
- 06 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 07 Jun 2024, 16:05:13 UTC
- Prior SEC filing
- 22 Jun 2023
- Next SEC filing
- 13 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brett Hagen, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David Hallal filed Form 4 for Allovir, Inc. (KLRS) on 07 Jun 2024.
Change
- Previous filing in this sequence was filed on 22 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ALVR
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +35,000
- Change %
- +1.7%
- Price
- $0.000000
- Shares after
- 2,143,662
- Date
- 06 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
ALVR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 720,965
- Date
- 06 Jun 2024
- Ownership
- Shares held by The Hallal Family Irrevocable Trust 2012
- Footnotes
- F2
ALVR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 138,153
- Date
- 06 Jun 2024
- Ownership
- Shares held by Terrie A. Hallal Family Irrevocable Trust 2012
- Footnotes
- F3
ALVR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 16,674,766
- Date
- 06 Jun 2024
- Ownership
- Shares held by ElevateBio LLC
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) June 6, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.
Footnote F2
Shares held by The Hallal Family Irrevocable Trust 2012, for which the Reporting Person's spouse serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Footnote F3
Shares held by Terrie A. Hallal Family Irrevocable Trust 2012, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Footnote F4
Shares held by ElevateBio LLC ("ElevateBio"). The Reporting Person is the Chairman and Chief Executive Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.